[go: up one dir, main page]

SG11201900868XA - Ido1 inhibitor and preparation method and application thereof - Google Patents

Ido1 inhibitor and preparation method and application thereof

Info

Publication number
SG11201900868XA
SG11201900868XA SG11201900868XA SG11201900868XA SG11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA
Authority
SG
Singapore
Prior art keywords
application
preparation
ido1 inhibitor
ido1
inhibitor
Prior art date
Application number
SG11201900868XA
Inventor
Yang Zhang
Zhifei Fu
Miaorong Luo
Jian Li
Shuhui Chen
Original Assignee
Shandong luye pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong luye pharmaceutical co ltd filed Critical Shandong luye pharmaceutical co ltd
Publication of SG11201900868XA publication Critical patent/SG11201900868XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound as an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.
SG11201900868XA 2016-08-02 2017-08-02 Ido1 inhibitor and preparation method and application thereof SG11201900868XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610631523 2016-08-02
CN201610797622 2016-08-30
PCT/CN2017/095571 WO2018024208A1 (en) 2016-08-02 2017-08-02 Ido1 inhibitor and preparation method and application thereof

Publications (1)

Publication Number Publication Date
SG11201900868XA true SG11201900868XA (en) 2019-02-27

Family

ID=61073210

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900868XA SG11201900868XA (en) 2016-08-02 2017-08-02 Ido1 inhibitor and preparation method and application thereof

Country Status (11)

Country Link
US (1) US20190169140A1 (en)
EP (1) EP3495354A4 (en)
JP (1) JP2019527699A (en)
KR (1) KR20190034318A (en)
CN (1) CN109563060B (en)
AU (1) AU2017306487A1 (en)
BR (1) BR112019001980A2 (en)
CA (1) CA3032544A1 (en)
RU (1) RU2019104899A (en)
SG (1) SG11201900868XA (en)
WO (1) WO2018024208A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106062A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN107033097B (en) * 2016-02-04 2022-02-08 江苏恒瑞医药股份有限公司 Oxadiazole derivative, preparation method and medical application thereof
UY37466A (en) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
WO2018214958A1 (en) * 2017-05-25 2018-11-29 山东绿叶制药有限公司 Crystal form of ido1 inhibitor and preparation method therefor
CN109942565B (en) * 2017-12-20 2021-03-26 海创药业股份有限公司 Indoleamine-2, 3-dioxygenase inhibitor and preparation method and application thereof
WO2019149159A1 (en) * 2018-02-02 2019-08-08 山东绿叶制药有限公司 Composition comprising oxadiazole derivative, preparation method therefor and use thereof
CN110143955B (en) * 2018-02-11 2023-01-20 中国科学院上海药物研究所 Oxadiazole derivative containing heterocyclic side chain, synthetic method and application thereof
CN110343098B (en) * 2018-04-04 2023-05-26 中国科学院上海药物研究所 Oxadiazole compound, preparation method, pharmaceutical composition and application thereof
CN110407765B (en) * 2018-04-28 2022-12-06 上海挚盟医药科技有限公司 1,2,5-oxadiazole derivative, preparation method and medical application thereof
CN109438513B (en) * 2018-10-25 2020-05-12 中国药科大学 IDO1 inhibitor containing substituted phosphonamido ester, its preparation method and application
CN112315954A (en) * 2020-11-24 2021-02-05 烟台大学 Paclitaxel and IDO1 small molecule inhibitor compound pharmaceutical composition and application thereof
CN114409610B (en) * 2022-03-29 2022-06-10 山东大学 Oxadiazole derivatives, their preparation and use
CN119371415A (en) * 2023-09-28 2025-01-28 西安近代化学研究所 Preparation method of 3,3-bis(4-azidofurazan-3-oxymethyl)oxetane

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02461B (en) * 2005-05-10 2017-02-20 Incyte Holdings Corp INDOLEAMINE 2,3-DIOXYGENASE MODULATORS AND METHODS FOR THE USE OF THE SAME
EP1971583B1 (en) * 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
SG10201805844QA (en) * 2008-07-08 2018-08-30 Incyte Holdings Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN105481789B (en) * 2014-09-15 2020-05-19 中国科学院上海有机化学研究所 A kind of indoleamine-2,3-dioxygenase inhibitor and preparation method thereof
CN106565696B (en) * 2015-10-09 2020-07-28 江苏恒瑞医药股份有限公司 Oxadiazole derivative, preparation method and medical application thereof
WO2017106062A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN105646389B (en) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 A kind of sulfamic acid ester as indoleamine-2,3-dioxygenase inhibitor and its preparation method and use
WO2018072697A1 (en) * 2016-10-17 2018-04-26 上海医药集团股份有限公司 Oxadiazole ring-containing compound, preparation method therefor, and intermediate, composite, and application thereof
UY37466A (en) * 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
WO2018214958A1 (en) * 2017-05-25 2018-11-29 山东绿叶制药有限公司 Crystal form of ido1 inhibitor and preparation method therefor
WO2018228381A1 (en) * 2017-06-13 2018-12-20 山东绿叶制药有限公司 Method for preparing 1,2,5-oxadiazole compound, and intermediate thereof
WO2019047920A1 (en) * 2017-09-08 2019-03-14 山东绿叶制药有限公司 Crystal form of oxadiazole derivative as ido1 inhibitor and preparation method therefor
WO2019149159A1 (en) * 2018-02-02 2019-08-08 山东绿叶制药有限公司 Composition comprising oxadiazole derivative, preparation method therefor and use thereof

Also Published As

Publication number Publication date
JP2019527699A (en) 2019-10-03
RU2019104899A3 (en) 2020-08-21
AU2017306487A1 (en) 2019-02-21
EP3495354A4 (en) 2020-01-15
US20190169140A1 (en) 2019-06-06
RU2019104899A (en) 2020-08-21
BR112019001980A2 (en) 2019-05-07
CN109563060B (en) 2021-01-01
WO2018024208A1 (en) 2018-02-08
CA3032544A1 (en) 2018-02-08
KR20190034318A (en) 2019-04-01
CN109563060A (en) 2019-04-02
EP3495354A1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
EA201792259A1 (en) BENZIMIDAZOLIC AND IMIDAZOPIRIDINE CARBOXIMIDAMIDE COMPOUNDS
PH12016500024A1 (en) Bromodomain inhibitor
CL2018000318A1 (en) Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201792116A1 (en) JANUS KINASE INHIBITOR
WO2016011390A8 (en) Irak4 inhibiting agents
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP4609866A3 (en) Oxysterols and methods of use thereof
WO2018086591A8 (en) Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
MX2018009633A (en) Inhibitor of indoleamine-2,3-dioxygenase (ido).
SA519410865B1 (en) Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
MY182884A (en) Pyrazole-amide compound and medicinal uses therefor
AR103680A1 (en) BACE1 SELECTIVE INHIBITORS
CY1124251T1 (en) CARBOXAMIDE DERIVATIVES
MX2017007607A (en) Inhibitors of cellular necrosis and related methods.
PH12017501652B1 (en) Kv1.3 inhibitors and their medical application
WO2014153495A9 (en) Novel stat3 inhibitors
MX394624B (en) SELECTIVE HDAC6 INHIBITORS, METHODS OF PREPARATION AND APPLICATION OF THE SAME.
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
MX394860B (en) Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
PH12022551241A1 (en) Egfr inhibitors